The 18th patient was treated for phase one, and the patient returned to the trial for an additional set of injections.
“In some patients, it appears that the disease is no longer progressing, but it is too early to know if the result from that small number of patients is meaningful,” said Eva Feldman, MD, PhD, the principal investigator of the trial and an unpaid consultant to Neuralstem.
More Articles on Stem Cells:
11 Sports Medicine Surgeons Researching Biologics
Grayslake Suite of Illinois Bone & Joint Institute Slated to Open Soon
Institute of Regenerative and Molecular Orthopedics Hopes to Pioneer Stem Cell Harvesting
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.